Cargando…

The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity

Prion diseases are fatal neurodegenerative conditions of humans and vertebrate species. The transmissible prion agent is a novel infectious particle composed principally of PrP (Sc), an abnormal isomer of the normal host protein PrP (C). The only reliable method to detect mammalian prion infectivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Thackray, Alana M., Andréoletti, Olivier, Bujdoso, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998032/
https://www.ncbi.nlm.nih.gov/pubmed/29946445
http://dx.doi.org/10.12688/f1000research.14753.1
_version_ 1783331170615820288
author Thackray, Alana M.
Andréoletti, Olivier
Bujdoso, Raymond
author_facet Thackray, Alana M.
Andréoletti, Olivier
Bujdoso, Raymond
author_sort Thackray, Alana M.
collection PubMed
description Prion diseases are fatal neurodegenerative conditions of humans and vertebrate species. The transmissible prion agent is a novel infectious particle composed principally of PrP (Sc), an abnormal isomer of the normal host protein PrP (C). The only reliable method to detect mammalian prion infectivity is by bioassay, invariably in a vertebrate host. The current prion bioassays typically involve intracerebral or peripheral inoculation of test material into the experimental host and subsequent euthanasia when clinical signs of terminal prion disease become evident. It may be months or years before the onset of clinical disease becomes evident and a pre-determined clinical end-point is reached. Consequently, bioassay of prion infectivity in vertebrate species is cumbersome, time consuming, expensive, and increasingly open to ethical debate because these animals are subjected to terminal neurodegenerative disease. Prions are a significant risk to public health through the potential for zoonotic transmission of animal prion diseases. Attention has focussed on the measurement of prion infectivity in different tissues and blood from prion-infected individuals in order to determine the distribution of infectious prions in diseased hosts. New animal models are required in order to replace or reduce, where possible, the dependency on the use of vertebrate species, including the ‘gold standard’ mouse prion bioassay, to assess prion infectivity levels. Here we highlight the development of a  Drosophila-based prion bioassay, a highly sensitive and rapid invertebrate animal system that can efficiently detect mammalian prions. This novel invertebrate model system will be of considerable interest to biologists who perform prion bioassays as it will promote reduction and replacement in the number of sentient animals currently used for this purpose. This article is a composite of previous methods that provides an overview of the methodology of the model and discusses the experimental data to promote its viability for use instead of more sentient hosts.
format Online
Article
Text
id pubmed-5998032
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-59980322018-06-25 The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity Thackray, Alana M. Andréoletti, Olivier Bujdoso, Raymond F1000Res Method Article Prion diseases are fatal neurodegenerative conditions of humans and vertebrate species. The transmissible prion agent is a novel infectious particle composed principally of PrP (Sc), an abnormal isomer of the normal host protein PrP (C). The only reliable method to detect mammalian prion infectivity is by bioassay, invariably in a vertebrate host. The current prion bioassays typically involve intracerebral or peripheral inoculation of test material into the experimental host and subsequent euthanasia when clinical signs of terminal prion disease become evident. It may be months or years before the onset of clinical disease becomes evident and a pre-determined clinical end-point is reached. Consequently, bioassay of prion infectivity in vertebrate species is cumbersome, time consuming, expensive, and increasingly open to ethical debate because these animals are subjected to terminal neurodegenerative disease. Prions are a significant risk to public health through the potential for zoonotic transmission of animal prion diseases. Attention has focussed on the measurement of prion infectivity in different tissues and blood from prion-infected individuals in order to determine the distribution of infectious prions in diseased hosts. New animal models are required in order to replace or reduce, where possible, the dependency on the use of vertebrate species, including the ‘gold standard’ mouse prion bioassay, to assess prion infectivity levels. Here we highlight the development of a  Drosophila-based prion bioassay, a highly sensitive and rapid invertebrate animal system that can efficiently detect mammalian prions. This novel invertebrate model system will be of considerable interest to biologists who perform prion bioassays as it will promote reduction and replacement in the number of sentient animals currently used for this purpose. This article is a composite of previous methods that provides an overview of the methodology of the model and discusses the experimental data to promote its viability for use instead of more sentient hosts. F1000 Research Limited 2018-05-15 /pmc/articles/PMC5998032/ /pubmed/29946445 http://dx.doi.org/10.12688/f1000research.14753.1 Text en Copyright: © 2018 Thackray AM et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Method Article
Thackray, Alana M.
Andréoletti, Olivier
Bujdoso, Raymond
The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity
title The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity
title_full The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity
title_fullStr The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity
title_full_unstemmed The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity
title_short The use of PrP transgenic Drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity
title_sort use of prp transgenic drosophila to replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity
topic Method Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998032/
https://www.ncbi.nlm.nih.gov/pubmed/29946445
http://dx.doi.org/10.12688/f1000research.14753.1
work_keys_str_mv AT thackrayalanam theuseofprptransgenicdrosophilatoreplaceandreducevertebratehostsinthebioassayofmammalianprioninfectivity
AT andreolettiolivier theuseofprptransgenicdrosophilatoreplaceandreducevertebratehostsinthebioassayofmammalianprioninfectivity
AT bujdosoraymond theuseofprptransgenicdrosophilatoreplaceandreducevertebratehostsinthebioassayofmammalianprioninfectivity
AT thackrayalanam useofprptransgenicdrosophilatoreplaceandreducevertebratehostsinthebioassayofmammalianprioninfectivity
AT andreolettiolivier useofprptransgenicdrosophilatoreplaceandreducevertebratehostsinthebioassayofmammalianprioninfectivity
AT bujdosoraymond useofprptransgenicdrosophilatoreplaceandreducevertebratehostsinthebioassayofmammalianprioninfectivity